HRP20120477T1 - Nova anti plgf protutijela - Google Patents
Nova anti plgf protutijela Download PDFInfo
- Publication number
- HRP20120477T1 HRP20120477T1 HRP20120477TT HRP20120477T HRP20120477T1 HR P20120477 T1 HRP20120477 T1 HR P20120477T1 HR P20120477T T HRP20120477T T HR P20120477TT HR P20120477 T HRP20120477 T HR P20120477T HR P20120477 T1 HRP20120477 T1 HR P20120477T1
- Authority
- HR
- Croatia
- Prior art keywords
- image
- artificial sequence
- antigen
- dna
- misc
- Prior art date
Links
- 102100035194 Placenta growth factor Human genes 0.000 claims abstract 9
- 239000012634 fragment Substances 0.000 claims abstract 4
- 230000002265 prevention Effects 0.000 claims abstract 2
- 239000000427 antigen Substances 0.000 claims 18
- 102000036639 antigens Human genes 0.000 claims 18
- 108091007433 antigens Proteins 0.000 claims 18
- 108091034117 Oligonucleotide Proteins 0.000 claims 12
- 241000699660 Mus musculus Species 0.000 claims 10
- 108010082093 Placenta Growth Factor Proteins 0.000 claims 8
- 108091033319 polynucleotide Proteins 0.000 claims 4
- 102000040430 polynucleotide Human genes 0.000 claims 4
- 239000002157 polynucleotide Substances 0.000 claims 4
- 108010047041 Complementarity Determining Regions Proteins 0.000 claims 3
- HVLSXIKZNLPZJJ-TXZCQADKSA-N HA peptide Chemical compound C([C@@H](C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](C(C)C)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(=O)N[C@@H](C)C(O)=O)NC(=O)[C@H]1N(CCC1)C(=O)[C@@H](N)CC=1C=CC(O)=CC=1)C1=CC=C(O)C=C1 HVLSXIKZNLPZJJ-TXZCQADKSA-N 0.000 claims 3
- 108010021625 Immunoglobulin Fragments Proteins 0.000 claims 3
- 102000008394 Immunoglobulin Fragments Human genes 0.000 claims 3
- 206010028980 Neoplasm Diseases 0.000 claims 3
- 201000011510 cancer Diseases 0.000 claims 3
- 150000001413 amino acids Chemical group 0.000 claims 2
- 230000001575 pathological effect Effects 0.000 claims 2
- FWMNVWWHGCHHJJ-SKKKGAJSSA-N 4-amino-1-[(2r)-6-amino-2-[[(2r)-2-[[(2r)-2-[[(2r)-2-amino-3-phenylpropanoyl]amino]-3-phenylpropanoyl]amino]-4-methylpentanoyl]amino]hexanoyl]piperidine-4-carboxylic acid Chemical compound C([C@H](C(=O)N[C@H](CC(C)C)C(=O)N[C@H](CCCCN)C(=O)N1CCC(N)(CC1)C(O)=O)NC(=O)[C@H](N)CC=1C=CC=CC=1)C1=CC=CC=C1 FWMNVWWHGCHHJJ-SKKKGAJSSA-N 0.000 claims 1
- 206010006187 Breast cancer Diseases 0.000 claims 1
- 208000026310 Breast neoplasm Diseases 0.000 claims 1
- 206010009944 Colon cancer Diseases 0.000 claims 1
- 206010061218 Inflammation Diseases 0.000 claims 1
- 241001529936 Murinae Species 0.000 claims 1
- 241000699666 Mus <mouse, genus> Species 0.000 claims 1
- 206010061902 Pancreatic neoplasm Diseases 0.000 claims 1
- 230000000996 additive effect Effects 0.000 claims 1
- 230000033115 angiogenesis Effects 0.000 claims 1
- 239000004037 angiogenesis inhibitor Substances 0.000 claims 1
- 230000015572 biosynthetic process Effects 0.000 claims 1
- 210000004204 blood vessel Anatomy 0.000 claims 1
- 208000029742 colonic neoplasm Diseases 0.000 claims 1
- 150000001875 compounds Chemical class 0.000 claims 1
- 239000003937 drug carrier Substances 0.000 claims 1
- 208000030533 eye disease Diseases 0.000 claims 1
- 238000000338 in vitro Methods 0.000 claims 1
- 230000004054 inflammatory process Effects 0.000 claims 1
- 230000005764 inhibitory process Effects 0.000 claims 1
- 208000015486 malignant pancreatic neoplasm Diseases 0.000 claims 1
- 201000001441 melanoma Diseases 0.000 claims 1
- 239000012528 membrane Substances 0.000 claims 1
- 238000000034 method Methods 0.000 claims 1
- 239000000203 mixture Substances 0.000 claims 1
- 201000002528 pancreatic cancer Diseases 0.000 claims 1
- 208000008443 pancreatic carcinoma Diseases 0.000 claims 1
- 230000035699 permeability Effects 0.000 claims 1
- 239000008194 pharmaceutical composition Substances 0.000 claims 1
- 239000000825 pharmaceutical preparation Substances 0.000 claims 1
- 208000002815 pulmonary hypertension Diseases 0.000 claims 1
- 101001001487 Homo sapiens Phosphatidylinositol-glycan biosynthesis class F protein Proteins 0.000 abstract 1
- 101000595923 Homo sapiens Placenta growth factor Proteins 0.000 abstract 1
- 208000034038 Pathologic Neovascularization Diseases 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/22—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against growth factors ; against growth regulators
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
- A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P41/00—Drugs used in surgical methods, e.g. surgery adjuvants for preventing adhesion or for vitreum substitution
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/14—Vasoprotectives; Antihaemorrhoidals; Drugs for varicose therapy; Capillary stabilisers
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Immunology (AREA)
- Molecular Biology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Genetics & Genomics (AREA)
- Biophysics (AREA)
- Biochemistry (AREA)
- Epidemiology (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Microbiology (AREA)
- Mycology (AREA)
- Endocrinology (AREA)
- Pain & Pain Management (AREA)
- Hematology (AREA)
- Physical Education & Sports Medicine (AREA)
- Vascular Medicine (AREA)
- Surgery (AREA)
- Pulmonology (AREA)
- Ophthalmology & Optometry (AREA)
- Rheumatology (AREA)
- Diabetes (AREA)
- Peptides Or Proteins (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Investigating Or Analysing Biological Materials (AREA)
Abstract
Molekula koji veže antigen sposoban da veže PlGFnaznačena time da sadrži CDR područja koja odgovaraju sekvencama SEQ ID NO do Patent sadrži još patentnih zahtjeva
Claims (20)
1. Molekula koji veže antigen sposoban da veže PlGF, naznačena time, da sadrži CDR područja koja odgovaraju sekvencama SEQ ID NO: 17 do 22.
2. Molekula koja veže antigen prema zahtjevu 1, naznačena time, da je navedena molekula odabrana iz skupine koja sadrži Fab, Fab' ili F(ab')2, kombinacije barem dva područja koja određuju komplementarnost (CDR), jedno-lančanog varijabilnog područja koje je spojeno na membranu ili pojedinačnu varijabilnu domenu.
3. Molekula koja veže antigen prema zahtjevu 1, naznačena time, da sadrži varijabilno područje teškog lanca koji sadrži sekvencu SEQ ID NO: 2, te također sadrži varijabilno područje lakog lanca koji sadrži sekvencu SEQ ID NO. 4.
4. Molekula koja veže antigen prema bilo kojem od zahtjeva 1 do 3, naznačena time, da navedena molekula predstavlja protutijelo 16D3, proizvedeno u staničnoj liniji koja je pohranjena kao LMBP 6399CB, ili njegov fragment.
5. Molekula koja veže antigen prema bilo kojem od zahtjeva 1 do 3, naznačena time, da navedena molekula predstavlja humanizirano protutijelo ili fragment protutijela.
6. Molekula koja veže antigen prema zahtjevu 1, naznačena time, da navedena molekula predstavlja jedno-lančani varijabilni fragment.
7. Molekula koja veže antigen prema zahtjevu 1, naznačena time, da navedena molekula sadrži amino-kiselinsku sekvencu SEQ ID NO: 24.
8. Molekula koja veže antigen prema zahtjevu 1, naznačena time, da navedena molekula sadrži amino-kiselinsku sekvencu SEQ ID NO: 26.
9. Stanična linija, naznačena time, da proizvodi molekulu koja veže antigen prema zahtjevu 1.
10. Stanična linija prema zahtjevu 9, naznačena time, da je navedena linija pohranjena kao LMBP 6399CB.
11. Farmaceutski pripravak, naznačen time, da kao aktivnu komponentu sadrži molekulu koja veže PlGF prema bilo kojem od zahtjeva 1 do 8 u smjesi sa farmaceutski prihvatljivim nosačem.
12. Farmaceutski pripravak prema zahtjevu 11, naznačen time, da nadalje sadrži terapeutski učinkovitu količinu drugog anti-angiogenog sredstva.
13. Polinukleotid, naznačen time, da kodira molekulu koja veže antigen prema bilo kojem od zahtjeva 1 do 8.
14. Uporaba molekule koja veže antigen prema bilo kojem od zahtjeva 1 do 8, naznačena time, da se navedena molekula upotrebljava za pretraživanje spojeva sa aditivnim učinkom u inhibiciji PlGF kod liječenja raka.
15. Uporaba molekule koja veže antigen prema bilo kojem od zahtjeva 1 do 8, naznačena time, da se navedena molekula koristi kao in vitro dijagnostički alat.
16. Uporaba molekule koja veže antigen prema bilo kojem od zahtjeva 1 do 8, naznačena time, da se navedena molekula koristi za pretraživanje drugih molekula koje vežu antigen, a koje su sposobne vezati isti epitop iz PlGF.
17. Postupak za odabir molekula koje vežu antigen i koje su sposobne vezati isti PlGF epitop kao i protutijelo 16D3 prema zahtjevu 4, naznačen time, da sadrži korake:
a) osiguravanja molekule koja veže PlGF; te
b) odabira molekule koja veže PlGF, a koja je sposobna vezati isti PlGF epitop kao i protutijelo 16D3 bazirano na reakciji sa navedenim epitopom ili bazirano na ogledu sa protutijelom 16D3.
18. Molekula koja veže antigen prema bilo kojem od zahtjeva 1 do 8 ili polinukleotid prema zahtjevu 13, naznačeni time, da se upotrebljavanju kod liječenja i/ili sprječavanja neželjene angiogeneze kod patoloških stanja sisavaca.
19. Molekula koja veže antigen ili polinukleotid prema zahtjevu 18, naznačeni time, da je navedeno patološko stanje odabrano iz skupine koja sadrži rak, upalu, nastanak adhezije, bolesti oka, plućnu hipertenziju i propusnost stijenki krvnih žila.
20. Molekula koja veže antigen ili polinukleotid prema zahtjevu 19, naznačeni time, da je navedeni rak odabran iz skupine koja sadrži rak debelog crijeva, rak dojke, rak gušterače i melanome.
LISTA SEKVENCI
POPIS SEKVENCI
<110> Thromb-X nv
Collen Research Foundation vzw
Vlaams Interuniversitair Instituut voor Biotechnologie (VIB)
Stassen, Jean-Marie
Carmeliet, Peter
Collen, Desire
<120> NOVA ANTI-PLGF PROTUTIJELA
<130> T3326-PCT
<150> US 60/664,768
<151> 2005-03-24
<160> 30
<170> PatentIn verzija 3.3
<210> 1
<211> 348
<212> DNK
<213> Mus musculus
<220>
<221> CDS
<222> (1)..(348)
<223> mišji varijabilni dio teškog lanca 16D3
<400> 1
[image]
[image]
<210> 2
<211> 116
<212> PRT
<213> Mus musculus
<400> 2
[image]
<210> 3
<211> 336
<212> DNK
<213> Mus musculus
<220>
<221> CDS
<222> (1) .. (336)
<223> mišji varijabilni dio lakog lanca 16D3
<400> 3
[image]
<210> 4
<211> 112
<212> PRT
<213> Mus musculus
<400> 4
[image]
[image]
<210> 5
<211> 348
<212> DNK
<213> Umjetna sekvenca
<220>
<223> Humanizirani fragment protutijela
<220>
<221> CDS
<222> (1)..(348)
<223> Humanizirani varijabilni dio teškog lanca 16D3
<400> 5
[image]
[image]
<210> 6
<211> 116
<212> PRT
<213> Umjetna sekvenca
<220>
<223> Sintetički konstrukt
<400> 6
[image]
<210> 7
<211> 336
<212> DNK
<213> Umjetna sekvenca
<220>
<223> Humanizirani fragment protutijela
<220>
<221> CDS
<222> (1)..(336)
<223> Humanizirani varijabilni dio lakog lanca 16D3
<400> 7
[image]
<210> 8
<211> 112
<212> PRT
<213> Umjetna sekvenca
<220>
<223> Sintetički konstrukt
<400> 8
[image]
<210> 9
<211> 24
<212> DNK
<213> Umjetna sekvenca
<220>
<223> oligonukleotidna početnica
<400> 9
atggratgga gctgkatcwt thtc 24
<210> 10
<211> 25
<212> DNK
<213> Umjetna sekvenca
<220>
<223> oligonukleotidna početnica
<400> 10
casaymcagg ggccagtgga tagac 25
<210> 11
<211> 27
<212> DNK
<213> Umjetna sekvenca
<220>
<223> oligonukleotidna početnica
<400> 11
atgragtcac akacycaggt cttyrta 27
<210> 12
<211> 24
<212> DNK
<213> Umjetna sekvenca
<220>
<223> oligonukleotidna početnica
<400> 12
gctcactgga tggtgggaag atgg 24
<210> 13
<211> 31
<212> DNK
<213> Umjetna sekvenca
<220>
<223> oligonukleotidna početnica
<400> 13
ccaccggtga cattgtgctg acccagtctc c 31
<210> 14
<211> 34
<212> DNK
<213> Umjetna sekvenca
<220>
<223> oligonukleotidna početnica
<400> 14
caccgtacgt tttatttcca actttgtccc cgag 34
<210> 15
<211> 22
<212> DNK
<213> Umjetna sekvenca
<220>
<223> oligonukleotidna početnica
<400> 15
caggtccagc tgcagcagtc tg 22
<210> 16
<211> 40
<212> DNK
<213> Umjetna sekvenca
<220>
<223> oligonukleotidna početnica
<400> 16
gatgggccct tggtcgacgc tgaggagact gtgagcaggg 40
<210> 17
<211> 8
<212> PRT
<213> Mus musculus
<220>
<221> misc
<222> (1)..(8)
<223> CDR1 teški lanac 16D3
<400> 17
[image]
<210> 18
<211> 8
<212> PRT
<213> Mus musculus
<220>
<221> MISC FEATURE
<222> (1)..(8)
<223> CDR2 teški lanac 16D3
<400> 18
[image]
<210> 19
<211> 9
<212> PRT
<213> Mus musculus
<220>
<221> MISC_FEATURE
<222> (1)..(9)
<223> CDR3 teški lanac 16D3
<400> 19
[image]
<210> 20
<211> 12
<212> PRT
<213> Mus musculus
<220>
<221> misc
<222> (1)..(12)
<223> CDR1 laki lanac 16D3
<400> 20
[image]
<210> 21
<211> 3
<212> PRT
<213> Mus musculus
<220>
<221> misc
<222> (1)..(3)
<223> CDR2 laki lanac 16D3
<400> 21
[image]
<210> 22
<211> 8
<212> PRT
<213> Mus musculus
<220>
<221> MISC_FEATURE
<222> (1)..(8)
<223> CDR3 laki lanac 16D3
<400> 22
[image]
<210> 23
<211> 786
<212> DNK
<213> Umjetna sekvenca
<220>
<223> 16D3 ScFv
<220>
<221> CDS
<222> (1)..(786)
<220>
<221> misc
<222> (1)..(348)
<223> Teški lanac
<220>
<221> misc
<222> (349)..(393)
<223> Linker
<220>
<221> misc
<222> (394)..(729)
<223> Laki lanac
<220>
<221> misc
<222> (736)..(762)
<223> HA-Tag
<220>
<221> misc
<222> (769)..(786)
<223> His-Tag
<400> 23
[image]
[image]
[image]
<210> 24
<211> 262
<212> PRT
<213> Umjetna sekvenca
<220>
<223> Sintetički konstrukt
<400> 24
[image]
[image]
<210> 25
<211> 786
<212> DNK
<213> Umjetna sekvenca
<220>
<223> Humanizirana 16D3 ScFv
<220>
<221> CDS
<222> (1)..(786)
<220>
<221> misc
<222> (1)..(348)
<223> Teški lanac
<220>
<221> misc
<222> (349)..(393)
<223> linker
<220>
<221> misc
<222> (394)..(729)
<223> Laki lanac
<220>
<221> misc
<222> (736)..(762)
<223> HA-tag
<220>
<221> misc
<222> (769)..(786)
<223> HA-tag
<400> 25
[image]
[image]
<210> 26
<211> 262
<212> PRT
<213> Umjetna sekvenca
<220>
<223> Sintetički konstrukt
<400> 26
[image]
[image]
[image]
<210> 27
<211> 22
<212> DNK
<213> Umjetna sekvenca
<220>
<223> oligonukleotidna početnica
<400> 27
caggtccagc tgcagcagtc tg 22
<210> 28
<211> 40
<212> DNK
<213> Umjetna sekvenca
<220>
<223> oligonukleotidna početnica
<400> 28
gatgggccct tggtcgacgc tgaggagact gtgagcaggg 40
<210> 29
<211> 31
<212> DNK
<213> Umjetna sekvenca
<220>
<223> oligonukleotidna početnica
<400> 29
ccaccggtga cattgtgctg acccagtctc c 31
<210> 30
<211> 34
<212> DNK
<213> Umjetna sekvenca
<220>
<223> oligonukleotidna početnica
<400> 30
caccgtacgt tttatttcca actttgtccc cgag 34
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US66476805P | 2005-03-24 | 2005-03-24 | |
| PCT/BE2006/000023 WO2006099698A2 (en) | 2005-03-24 | 2006-03-24 | Novel anti-plgf antibody |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| HRP20120477T1 true HRP20120477T1 (hr) | 2012-07-31 |
Family
ID=36928446
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| HRP20120477TT HRP20120477T1 (hr) | 2005-03-24 | 2012-06-06 | Nova anti plgf protutijela |
Country Status (27)
| Country | Link |
|---|---|
| US (3) | US7875704B2 (hr) |
| EP (2) | EP1869085B1 (hr) |
| JP (2) | JP5164829B2 (hr) |
| KR (1) | KR101314014B1 (hr) |
| CN (1) | CN101184776B (hr) |
| AT (1) | ATE549358T1 (hr) |
| AU (2) | AU2006227571B8 (hr) |
| BR (1) | BRPI0609151B8 (hr) |
| CA (1) | CA2601267C (hr) |
| CY (1) | CY1113224T1 (hr) |
| DK (1) | DK1869085T3 (hr) |
| EA (1) | EA013970B1 (hr) |
| ES (2) | ES2565481T3 (hr) |
| HK (1) | HK1116803A1 (hr) |
| HR (1) | HRP20120477T1 (hr) |
| IL (1) | IL185754A (hr) |
| ME (1) | ME01446B (hr) |
| MX (1) | MX2007011735A (hr) |
| NO (1) | NO341877B1 (hr) |
| NZ (1) | NZ561763A (hr) |
| PL (1) | PL1869085T3 (hr) |
| PT (1) | PT1869085E (hr) |
| RS (1) | RS52372B (hr) |
| SI (1) | SI1869085T1 (hr) |
| UA (1) | UA94707C2 (hr) |
| WO (1) | WO2006099698A2 (hr) |
| ZA (1) | ZA200707258B (hr) |
Families Citing this family (45)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP1297016B1 (en) * | 2000-05-12 | 2006-03-22 | Vlaams Interuniversitair Instituut voor Biotechnologie vzw. | Use of inhibitors of placental growth factor for the treatment of pathological angiogenesis, pathological arteriogenesis, inflammation, tumour formation and/or vascular leakage |
| KR101314014B1 (ko) | 2005-03-24 | 2013-10-02 | 쓰롬보제닉스 엔.브이. | 신규한 항-ｐｌｇｆ 항체 |
| CN101534865A (zh) * | 2005-10-19 | 2009-09-16 | Ibc药品公司 | 生物活性装配体的制备方法及其用途 |
| EP2899209A1 (en) | 2008-04-29 | 2015-07-29 | Abbvie Inc. | Dual Variable Domain Immunoglobulins and uses thereof |
| CA2726087A1 (en) | 2008-06-03 | 2009-12-10 | Tariq Ghayur | Dual variable domain immunoglobulins and uses thereof |
| TW201006485A (en) | 2008-06-03 | 2010-02-16 | Abbott Lab | Dual variable domain immunoglobulins and uses thereof |
| NZ603698A (en) | 2008-07-08 | 2014-03-28 | Abbvie Inc | Prostaglandin e2 dual variable domain immunoglobulins and uses thereof |
| BRPI0920224A2 (pt) | 2008-10-02 | 2017-06-27 | Life Sciences Res Partners Vzw | inibição de plgf para tratar leucemia positiva para cromossoma filadélfia |
| MX2011006875A (es) * | 2008-12-23 | 2011-07-20 | Genentech Inc | Metodos y composiciones para uso en diagnostico de pacientes con cancer. |
| AU2010242840B2 (en) * | 2009-05-01 | 2014-04-17 | Abbvie Inc. | Dual variable domain immunoglobulins and uses thereof |
| PE20121530A1 (es) | 2009-09-01 | 2012-12-22 | Abbvie Inc | Inmunoglobulinas con dominio variable dual |
| CA2775959A1 (en) | 2009-10-15 | 2011-04-21 | Abbott Laboratories | Dual variable domain immunoglobulins and uses thereof |
| UY32979A (es) | 2009-10-28 | 2011-02-28 | Abbott Lab | Inmunoglobulinas con dominio variable dual y usos de las mismas |
| CN102791726B (zh) | 2010-03-10 | 2016-02-03 | 弗·哈夫曼-拉罗切有限公司 | 纯化免疫球蛋白溶液的方法 |
| ES2560219T3 (es) * | 2010-07-19 | 2016-02-17 | F. Hoffmann-La Roche Ag | Biomarcadores del plasma sanguíneo para terapias de combinación con bevacizumab para el tratamiento del cáncer pancreático |
| EP3252072A3 (en) | 2010-08-03 | 2018-03-14 | AbbVie Inc. | Dual variable domain immunoglobulins and uses thereof |
| US9046513B2 (en) | 2010-08-26 | 2015-06-02 | Abbvie Inc. | Dual variable domain immunoglobulins and uses thereof |
| EP2785739B1 (en) * | 2011-12-01 | 2017-03-15 | ThromboGenics N.V. | Improving trabeculectomy outcome |
| UY34558A (es) | 2011-12-30 | 2013-07-31 | Abbvie Inc | Proteínas de unión específicas duales dirigidas contra il-13 y/o il-17 |
| KR20180008921A (ko) | 2012-11-01 | 2018-01-24 | 애브비 인코포레이티드 | 항-ｖｅｇｆ／ｄｌｌ4 이원 가변 도메인 면역글로불린 및 이의 용도 |
| NZ627796A (en) | 2012-12-18 | 2017-07-28 | Icahn School Med Mount Sinai | Influenza virus vaccines and uses thereof |
| US9908930B2 (en) | 2013-03-14 | 2018-03-06 | Icahn School Of Medicine At Mount Sinai | Antibodies against influenza virus hemagglutinin and uses thereof |
| CN105324396A (zh) | 2013-03-15 | 2016-02-10 | 艾伯维公司 | 针对IL-1β和/或IL-17的双重特异性结合蛋白 |
| US10035847B2 (en) | 2013-10-02 | 2018-07-31 | The Rockefeller University | Amyloid protofibril antibodies and methods of use thereof |
| WO2016094881A2 (en) | 2014-12-11 | 2016-06-16 | Abbvie Inc. | Lrp-8 binding proteins |
| WO2016118937A1 (en) | 2015-01-23 | 2016-07-28 | Icahn School Of Medicine At Mount Sinai | Influenza virus vaccination regimens |
| TW201710286A (zh) | 2015-06-15 | 2017-03-16 | 艾伯維有限公司 | 抗ｖｅｇｆ、ｐｄｇｆ及／或其受體之結合蛋白 |
| CN104930353B (zh) * | 2015-07-10 | 2017-08-15 | 浙江大学 | 一种城市供水管网的调压减漏评估系统 |
| US20190031762A1 (en) | 2016-03-10 | 2019-01-31 | Thrombogenics Nv | Posterior ocular fibrosis inhibition by antagonizing placental growth factor |
| JP7237344B2 (ja) | 2016-06-15 | 2023-03-13 | アイカーン スクール オブ メディシン アット マウント サイナイ | インフルエンザウイルス血球凝集素タンパク質及びその使用 |
| WO2018187706A2 (en) | 2017-04-07 | 2018-10-11 | Icahn School Of Medicine At Mount Sinai | Anti-influenza b virus neuraminidase antibodies and uses thereof |
| CN109134650A (zh) * | 2018-09-10 | 2019-01-04 | 宁波奥丞生物科技有限公司 | 抗人plgf单克隆抗体的制备方法 |
| US20220220197A1 (en) | 2019-05-28 | 2022-07-14 | Vib Vzw | Cancer Treatment by Targeting Plexins in the Immune Compartment |
| WO2020239934A1 (en) | 2019-05-28 | 2020-12-03 | Vib Vzw | Cd8+ t-cells lacking plexins and their application in cancer treatment |
| WO2020260595A1 (en) | 2019-06-26 | 2020-12-30 | Oncurious Nv | Combination treatment of medulloblastoma using a placental growth factor inhibitor and a chemotherapeutic agent |
| EP3936868A1 (en) | 2020-07-10 | 2022-01-12 | Charité - Universitätsmedizin Berlin | A ratio between plgf and sflt1 is predictive for neural invasion in patients suffering from pancreatic cancer |
| WO2022063957A1 (en) | 2020-09-24 | 2022-03-31 | Vib Vzw | Biomarker for anti-tumor therapy |
| CN112358546B (zh) * | 2020-11-10 | 2022-04-01 | 宁波奥丞生物科技有限公司 | 杂交瘤细胞株9c1、plgf-1单克隆抗体及其应用 |
| WO2022099465A1 (zh) * | 2020-11-10 | 2022-05-19 | 宁波奥丞生物科技有限公司 | 杂交瘤细胞株9c1、plgf-1单克隆抗体及其制备方法和应用 |
| JP2023554520A (ja) | 2020-12-22 | 2023-12-27 | コビオレス エヌヴイ | テトラペプチド部分を含む化合物 |
| CN113999310A (zh) * | 2020-12-30 | 2022-02-01 | 江苏普若维生物技术有限责任公司 | 一种plgf单克隆抗体、试剂盒、其制备方法和应用 |
| WO2022167664A1 (en) | 2021-02-07 | 2022-08-11 | Cobiores Nv | Compounds comprising a tetrapeptidic moiety |
| CA3211257A1 (en) | 2021-02-17 | 2022-08-25 | Vib Vzw | Inhibition of slc4a4 in the treatment of cancer |
| WO2023118294A1 (en) | 2021-12-22 | 2023-06-29 | Vib Vzw | Inhibition of mitoferrin 2 as means for inhibiting cancer and cancer metastasis |
| WO2024033381A1 (en) | 2022-08-10 | 2024-02-15 | Vib Vzw | Inhibition of tcf4/itf2 in the treatment of cancer |
Family Cites Families (30)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| NZ207394A (en) | 1983-03-08 | 1987-03-06 | Commw Serum Lab Commission | Detecting or determining sequence of amino acids |
| US5770198A (en) | 1988-05-18 | 1998-06-23 | The Research Foundation Of The State Of New York | Platelet-specific chimeric 7E3 immunoglobulin |
| US5545806A (en) * | 1990-08-29 | 1996-08-13 | Genpharm International, Inc. | Ransgenic non-human animals for producing heterologous antibodies |
| IT1242149B (it) * | 1990-09-27 | 1994-02-16 | Consiglio Nazionale Ricerche | Sequenza di nucleotidi codificante per una proteina umana con proprieta' regolative dell'angiogenesi |
| ATE175241T1 (de) | 1992-04-03 | 1999-01-15 | Genentech Inc | Antikörper gegen alpha v beta 3 integrin |
| US6177401B1 (en) * | 1992-11-13 | 2001-01-23 | Max-Planck-Gesellschaft Zur Forderung Der Wissenschaften | Use of organic compounds for the inhibition of Flk-1 mediated vasculogenesis and angiogenesis |
| US5861499A (en) | 1994-02-10 | 1999-01-19 | Imclone Systems Incorporated | Nucleic acid molecules encoding the variable or hypervariable region of a monoclonal antibody that binds to an extracellular domain |
| IL117645A (en) | 1995-03-30 | 2005-08-31 | Genentech Inc | Vascular endothelial cell growth factor antagonists for use as medicaments in the treatment of age-related macular degeneration |
| CN1209068A (zh) | 1995-10-23 | 1999-02-24 | 海欧制药澳大利亚有限公司 | 作为基因治疗所用的dna载体的透明质酸及治疗异常视网膜血管化的vegf反义dna |
| AU738806B2 (en) | 1996-09-24 | 2001-09-27 | Merck & Co., Inc. | Gene therapy for inhibition of angiogenesis |
| US6986890B1 (en) | 1996-11-21 | 2006-01-17 | Kyowa Hakko Kogyo Co., Ltd. | Anti-human VEGF receptor Flt-1 monoclonal antibody |
| GB9723780D0 (en) | 1997-11-12 | 1998-01-07 | Univ Manchester | Regulation of ocular angiogenesis |
| DK1064382T3 (da) | 1998-03-17 | 2008-12-08 | Genentech Inc | Homologe polypeptider til VEGF og BMP1 |
| JPH11302193A (ja) * | 1998-04-22 | 1999-11-02 | Toagosei Co Ltd | 血管新生阻害剤 |
| CA2332336A1 (en) | 1998-05-26 | 1999-12-02 | Erik Depla | Method for expanding primate b cells selectively in immunocompromised mice and producing large numbers of antigen-specific b lymphocytes for the production of primate monoclonal antibodies |
| JP2001086982A (ja) | 1999-07-16 | 2001-04-03 | Shunpei Niida | 骨吸収調節薬 |
| US6733755B2 (en) | 2000-02-04 | 2004-05-11 | Supratek Pharma, Inc. | Ligand for vascular endothelial growth factor receptor |
| EP1297016B1 (en) * | 2000-05-12 | 2006-03-22 | Vlaams Interuniversitair Instituut voor Biotechnologie vzw. | Use of inhibitors of placental growth factor for the treatment of pathological angiogenesis, pathological arteriogenesis, inflammation, tumour formation and/or vascular leakage |
| WO2002097044A2 (en) * | 2001-05-25 | 2002-12-05 | Thomas Jefferson University | Alternative splice forms of proteins as basis for multiple therapeutic modalities |
| US7139817B1 (en) * | 2001-06-12 | 2006-11-21 | Network Appliance, Inc. | Managing configuration information for multiple devices |
| JP2005508298A (ja) | 2001-06-20 | 2005-03-31 | イムクローン システムズ インコーポレイティド | アテローム性動脈硬化症及び他の炎症性疾患を処置する方法 |
| ATE347908T1 (de) | 2002-01-29 | 2007-01-15 | Vlaams Interuniv Inst Biotech | Vorbeugung von gewebeadhäsion |
| JP5111729B2 (ja) | 2002-06-05 | 2013-01-09 | ジェネンテック， インコーポレイテッド | 肝成長及び肝保護のための組成物と方法 |
| AU2003251729A1 (en) | 2002-06-28 | 2004-01-19 | K.U.Leuven Research & Development | Use of antibodies against flt-1 for the treatment of osteoporosis |
| WO2004042085A2 (en) * | 2002-11-08 | 2004-05-21 | Primagen Holding B.V. | Method for quantifying a ratio between at least two nucleic acid sequences |
| CA2518357A1 (en) * | 2003-03-10 | 2004-09-23 | Callisto Pharmaceuticals, Inc. | Method of treating cancer with azaspirane compositions |
| US20050282233A1 (en) * | 2004-03-05 | 2005-12-22 | Ludwig Institute For Cancer Research | Multivalent antibody materials and methods for VEGF/PDGF family of growth factors |
| KR101314014B1 (ko) | 2005-03-24 | 2013-10-02 | 쓰롬보제닉스 엔.브이. | 신규한 항-ｐｌｇｆ 항체 |
| EP1904095B1 (en) | 2005-06-30 | 2013-05-29 | VIB, vzw | Treatment of liver cirrhosis and its complications |
| BRPI0920224A2 (pt) | 2008-10-02 | 2017-06-27 | Life Sciences Res Partners Vzw | inibição de plgf para tratar leucemia positiva para cromossoma filadélfia |
-
2006
- 2006-03-24 KR KR1020077024317A patent/KR101314014B1/ko active IP Right Grant
- 2006-03-24 PT PT06721544T patent/PT1869085E/pt unknown
- 2006-03-24 WO PCT/BE2006/000023 patent/WO2006099698A2/en active Application Filing
- 2006-03-24 RS RS20120249A patent/RS52372B/en unknown
- 2006-03-24 DK DK06721544.2T patent/DK1869085T3/da active
- 2006-03-24 ES ES11160897.2T patent/ES2565481T3/es active Active
- 2006-03-24 EA EA200702064A patent/EA013970B1/ru not_active IP Right Cessation
- 2006-03-24 EP EP06721544A patent/EP1869085B1/en active Active
- 2006-03-24 ES ES06721544T patent/ES2384110T3/es active Active
- 2006-03-24 ZA ZA200707258A patent/ZA200707258B/xx unknown
- 2006-03-24 UA UAA200711730A patent/UA94707C2/ru unknown
- 2006-03-24 SI SI200631343T patent/SI1869085T1/sl unknown
- 2006-03-24 JP JP2008502194A patent/JP5164829B2/ja not_active Expired - Fee Related
- 2006-03-24 EP EP11160897.2A patent/EP2447281B1/en not_active Not-in-force
- 2006-03-24 NZ NZ561763A patent/NZ561763A/en unknown
- 2006-03-24 PL PL06721544T patent/PL1869085T3/pl unknown
- 2006-03-24 CN CN2006800093279A patent/CN101184776B/zh not_active Expired - Fee Related
- 2006-03-24 CA CA2601267A patent/CA2601267C/en not_active Expired - Fee Related
- 2006-03-24 BR BRPI0609151A patent/BRPI0609151B8/pt not_active IP Right Cessation
- 2006-03-24 AT AT06721544T patent/ATE549358T1/de active
- 2006-03-24 ME MEP-2012-73A patent/ME01446B/me unknown
- 2006-03-24 AU AU2006227571A patent/AU2006227571B8/en not_active Ceased
- 2006-03-24 US US11/909,604 patent/US7875704B2/en not_active Expired - Fee Related
- 2006-03-24 MX MX2007011735A patent/MX2007011735A/es active IP Right Grant
-
2007
- 2007-09-05 IL IL185754A patent/IL185754A/en active IP Right Grant
- 2007-09-10 NO NO20074563A patent/NO341877B1/no not_active IP Right Cessation
-
2008
- 2008-03-11 HK HK08102805.3A patent/HK1116803A1/xx not_active IP Right Cessation
-
2010
- 2010-12-20 US US12/973,155 patent/US8758748B2/en active Active
-
2011
- 2011-03-23 AU AU2011201340A patent/AU2011201340B2/en not_active Ceased
-
2012
- 2012-02-01 JP JP2012019698A patent/JP2012136522A/ja active Pending
- 2012-06-06 HR HRP20120477TT patent/HRP20120477T1/hr unknown
- 2012-06-12 CY CY20121100535T patent/CY1113224T1/el unknown
-
2014
- 2014-02-03 US US14/170,997 patent/US9085617B2/en not_active Expired - Fee Related
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| HRP20120477T1 (hr) | Nova anti plgf protutijela | |
| JP5909442B2 (ja) | ヒト化ａｘｌ抗体 | |
| JP5981347B2 (ja) | Ｐｃｓｋ９アンタゴニスト | |
| JP2018527903A5 (hr) | ||
| CN109517067B (zh) | 一种抗人rankl抗体、其人源化抗体及它们的药物组合物和用途 | |
| JP2019536470A5 (hr) | ||
| KR102554634B1 (ko) | L1cam에 결합하는 신규한 결합 분자 특히 항체(cd171) | |
| HRP20181087T1 (hr) | Pripravak i postupak dijagnostike i liječenja bolesti povezanih s degeneracijom neurita | |
| JP2013091655A5 (hr) | ||
| JP2014503202A (ja) | ＴＮＦ−α結合性タンパク質 | |
| RU2014122990A (ru) | Способы комбинированной терапии с применением молекул, связывающихся с psl и pcrv pseudomonas | |
| WO2015191934A2 (en) | Blood-brain barrier (bbb) penetrating dual specific binding proteins for treating brain and neurological diseases | |
| JP2011509245A5 (hr) | ||
| EP2928919A2 (en) | Blood-brain barrier (bbb) penetrating dual specific binding proteins | |
| JP2015504421A5 (hr) | ||
| RU2018104283A (ru) | Антитела против ингибитора пути тканевого фактора и их применения | |
| JP7469284B2 (ja) | アクチビン２型受容体結合タンパク質及びその使用 | |
| JP2016503817A (ja) | アンチグラニュリシン抗体及びその使用方法 | |
| SG192047A1 (en) | Pathogenic mycobacteria-derived mannose-capped lipoarabinomannan antigen binding proteins | |
| KR20230132544A (ko) | 신규한 항-그렘린1 항체 | |
| CN109721656B (zh) | 靶向rankl的治疗性抗体 | |
| JP2018531625A5 (hr) | ||
| KR20220129030A (ko) | 항-Gal3 항체 및 사용 방법 | |
| CN112805297B (zh) | 抗人类pd-l1抗体及其用途 | |
| JPWO2021139780A5 (hr) |